3 completed, 1 terminated. 2 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Transcept Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder Ondansetron, Placebo - Obsessive-compulsive Disorder | Phase 2 | Terminated | Transcept Pharmaceuticals | 130 | 2011-01-01 | 2013-01-18 |
| Driving Performance After Middle of the Night Administration of 3.5 mg Zolpidem Tartrate Sublingual Tablet zopiclone, zolpidem tartrate sublingual tablet, Placebo (sublingual tablet) - Insomnia | Phase 1 | Completed | Transcept Pharmaceuticals | 40 | 2010-06-01 | 2012-02-14 |
| A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia zolpidem tartrate sublingual tablet, Placebo - Insomnia | Phase 3 | Completed | Transcept Pharmaceuticals | 295 | 2007-05-01 | 2012-02-14 |
| A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia zolpidem tartrate sublingual tablet 3.5mg, zolpidem tartrate sublingual tablet 1.75mg, Placebo - Insomnia | Phase 3 | Completed | Transcept Pharmaceuticals | 82 | 2006-04-01 | 2012-02-14 |
Sleep Initiation and Maintenance Disorders (3) · Obsessive-Compulsive Disorder (1)
Zolpidem (3) · Administration, Sublingual (1) · Ondansetron (1) · zopiclone (1)
United States (2) · Mexico (1) · Netherlands (1)
Thomas Roth, PhD (2) · Andrew Krystal, MD (1) · Annemiek Vermeeren, PhD (1) · Eric Hollander, MD (1) · Martin Scharf, PhD (1)